PharmaTalkRadio

As alternative funding pathways decrease and fewer research grants are administered, the relationship between biotech and academia must shift in order to continue to achieve innovation and development. In this podcast, featuring a panel discussion from the 2026 Chief Medical Officer Summit 360°, CMOs and academics present on these shifts in the global clinical development ecosystem, and how academia and biotech can better partner to develop new therapies for patients, with specific examples.

To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.

This podcast feature a panel discussion from the 2026 Chief Medical Officer Summit 360°, biotech CMOs and executives from CROs and consultancies. Together they discuss how small biotechs can accelerate clinical development with fit-for-purpose global clinical trial strategies. Specifically: 
The benefits and challenges of running clinical trials in different regions
When and at which phases to run clinical trials in different countries
Bridging data for approval applications
Managing global clinical trials in areas with different cultures and health systems
To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.

This podcast features a panel discussion from the 2026 Chief Medical Officer Summit 360°, with biotech CMOs and representatives from pharma companies. Together, they address how interactions around partnerships or acquisitions differ from those of investment from biotech companies and how CMOs can support those conversations. This includes:
How pharma companies analyze potential partners
What biotech companies can do to best partner with pharma 
How the CMO fits into various phases of transactions
Appreciating how different c-suite colleagues and direct reports experience these transactions
The different pharma teams CMOs will interact with
Common challenges to partnerships and how to pre-empt them
What happens after the acquisition
To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.

In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.  
More specifically, Mike discusses:  
How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments 
What questions sponsors should be asking of AI vendors, to pick the correct partner 
How sponsors have responded to the insights surfaced by this technology  
Why sponsors must adapt to a flexibility mindset in order to truly make changes with downstream impact